Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its ...
The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...
Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: “The sequential regulatory achievements of LBL-034-including Orphan Drug Designations from FDA, followed by FDA Fast Track ...
Hargreave Hale AIM VCT has invested in LabGenius Therapeutics, a drug discovery company combining high-throughput experimentation and machine learning (ML) to ...
IBI3003 targets GPRC5D, BCMA, and CD3, showing high response rates in heavily pretreated multiple myeloma patients. Fast track designation facilitates development and review of treatments addressing ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
A study will be conducted to review the methods the Department of Defense proposes for determining occupational exposure guidelines for trichloroethylene (TCE) in situations where vapor intrusion is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results